139 related articles for article (PubMed ID: 34750196)
1. The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner.
Arnold C; Demuth P; Seiwert N; Wittmann S; Boengler K; Rasenberger B; Christmann M; Huber M; Brunner T; Linnebacher M; Fahrer J
Mol Cancer Ther; 2022 Jan; 21(1):100-112. PubMed ID: 34750196
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Pardee TS; Lee K; Luddy J; Maturo C; Rodriguez R; Isom S; Miller LD; Stadelman KM; Levitan D; Hurd D; Ellis LR; Harrelson R; Manuel M; Dralle S; Lyerly S; Powell BL
Clin Cancer Res; 2014 Oct; 20(20):5255-64. PubMed ID: 25165100
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Anderson R; Miller LD; Isom S; Chou JW; Pladna KM; Schramm NJ; Ellis LR; Howard DS; Bhave RR; Manuel M; Dralle S; Lyerly S; Powell BL; Pardee TS
Nat Commun; 2022 Mar; 13(1):1673. PubMed ID: 35354808
[TBL] [Abstract][Full Text] [Related]
4. Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
Abaza MS; Bahman AM; Al-Attiyah RJ
World J Gastroenterol; 2008 Sep; 14(33):5162-75. PubMed ID: 18777593
[TBL] [Abstract][Full Text] [Related]
5. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo.
Zachar Z; Marecek J; Maturo C; Gupta S; Stuart SD; Howell K; Schauble A; Lem J; Piramzadian A; Karnik S; Lee K; Rodriguez R; Shorr R; Bingham PM
J Mol Med (Berl); 2011 Nov; 89(11):1137-48. PubMed ID: 21769686
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Mitochondrial Metabolism Leads to Selective Eradication of Cells Adapted to Acidic Microenvironment.
Koncošová M; Vrzáčková N; Křížová I; Tomášová P; Rimpelová S; Dvořák A; Vítek L; Rumlová M; Ruml T; Zelenka J
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639130
[TBL] [Abstract][Full Text] [Related]
7. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling.
Gao L; Xu Z; Huang Z; Tang Y; Yang D; Huang J; He L; Liu M; Chen Z; Teng Y
J Exp Clin Cancer Res; 2020 Apr; 39(1):73. PubMed ID: 32345326
[TBL] [Abstract][Full Text] [Related]
8. Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil.
Dörsam B; Göder A; Seiwert N; Kaina B; Fahrer J
Arch Toxicol; 2015 Oct; 89(10):1829-46. PubMed ID: 25526924
[TBL] [Abstract][Full Text] [Related]
9. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
Gallant JN; Allen JE; Smith CD; Dicker DT; Wang W; Dolloff NG; Navaraj A; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(3):239-51. PubMed ID: 21725213
[TBL] [Abstract][Full Text] [Related]
10. Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.
Neitzel C; Seiwert N; Göder A; Diehl E; Weber C; Nagel G; Stroh S; Rasenberger B; Christmann M; Fahrer J
Cells; 2019 Jul; 8(8):. PubMed ID: 31366086
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.
Guardado Rivas MO; Stuart SD; Thach D; Dahan M; Shorr R; Zachar Z; Bingham PM
PLoS One; 2022; 17(6):e0269620. PubMed ID: 35675354
[TBL] [Abstract][Full Text] [Related]
12. A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
Ramos H; Soares MIL; Silva J; Raimundo L; Calheiros J; Gomes C; Reis F; Monteiro FA; Nunes C; Reis S; Bosco B; Piazza S; Domingues L; Chlapek P; Vlcek P; Fabian P; Rajado AT; Carvalho ATP; Veselska R; Inga A; Pinho E Melo TMVD; Saraiva L
Cell Rep; 2021 Apr; 35(2):108982. PubMed ID: 33852837
[TBL] [Abstract][Full Text] [Related]
13. Helveticoside Exhibited p53-dependent Anticancer Activity Against Colorectal Cancer.
An N; Sun Y; Ma L; Shi S; Zheng X; Feng W; Shan Z; Han Y; Zhao L; Wu H
Arch Med Res; 2020 Apr; 51(3):224-232. PubMed ID: 32147288
[TBL] [Abstract][Full Text] [Related]
14. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
Wu X; Lu Y; Qin X
J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
Lycan TW; Pardee TS; Petty WJ; Bonomi M; Alistar A; Lamar ZS; Isom S; Chan MD; Miller AA; Ruiz J
PLoS One; 2016; 11(10):e0164244. PubMed ID: 27732654
[TBL] [Abstract][Full Text] [Related]
16. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of ARID1A in gastric cancer cells: a putative protective molecular mechanism against the Harakiri-mediated apoptosis pathway.
Sakuratani T; Takeuchi T; Yasufuku I; Iwata Y; Saigo C; Kito Y; Yoshida K
Virchows Arch; 2021 Mar; 478(3):401-411. PubMed ID: 32789692
[TBL] [Abstract][Full Text] [Related]
18. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
[TBL] [Abstract][Full Text] [Related]
19. The disulfide compound α-lipoic acid and its derivatives: A novel class of anticancer agents targeting mitochondria.
Dörsam B; Fahrer J
Cancer Lett; 2016 Feb; 371(1):12-9. PubMed ID: 26604131
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
